[Research progress on nanocarriers in drug delivery for pulmonary fibrosis]

Pulmonary fibrosis is a chronic and progressive lung disease with a high mortality rate. Current conventional therapeutic drugs are limited by problems such as low bioavailability, inadequate pulmonary drug concentration, poor targeting, and significant systemic toxicity, which restrict their clinical efficacy. In recent years, advances in nanotechnology have provided new strategies for its treatment. Nanocarriers have significantly improved drug delivery efficiency and therapeutic outcomes in pulmonary fibrosis, demonstrating promising application prospects. Therefore, this review summarizes the nanocarriers widely used in drug delivery for pulmonary fibrosis in recent years, aiming to provide new insights into drug delivery for this disease.